Current management of epithelial carcinoma of the ovary

Peter Zucker, N. B. Rosenshein

Research output: Contribution to journalArticle

Abstract

Most patients with epithelial cell cancer of the ovary are found to have advanced disease at the time of diagnosis (stage III or IV). Cytoreductive surgery should be attempted in all patients deemed appropriate surgical candidates. The goal of surgery is to remove as much tumor as feasible so that there are no isolated tumor implants within the abdominal cavity larger than 2 cm in diameter. Patients whose tumors can be resected to this extent are designated as having minimal residual disease (Group I). Patients in whom such cytoreductive surgery is not feasible or who are not appropriate surgical candidates usually have macroscopic residual disease (Group II). Group I patients, those with minimal residual disease, can be treated either with irradiation of the entire abdominal cavity or with systemic chemotherapy. The trend in most centers is to treat such patients with combination chemotherapy, although it remains unproven whether this is superior to radiation therapy. Group II patients, those with macroscopic residual disease, should not receive primary radiotherapeutic treatment. They may be treated with either single-agent or multiagent chemotherapy. While combination chemotherapy increases the chances of achieving a complete clinical response for individual patients, it is associated with increased toxicity. The risks associated with this toxicity must be considered in view of the fact that few of these patients will actually achieve such a response. The five-year survival rate for patients with epithelial cell cancer of the ovary has not changed for more than 30 years. Aggressive surgical, chemotherapeutic, and radiotherapeutic management is beginning to prolong survival. Hopefully, further investigation will allow the earlier diagnosis of patients with ovarian cancer and give the clinician new therapies for the management of this disease.

Original languageEnglish (US)
Pages (from-to)52-59
Number of pages8
JournalComprehensive Therapy
Volume11
Issue number5
StatePublished - Dec 1 1985

Fingerprint

Ovary
Carcinoma
Ovarian Neoplasms
Abdominal Cavity
Residual Neoplasm
Combination Drug Therapy
Epithelial Cells
Drug Therapy
Neoplasms
Disease Management
Early Diagnosis
Radiotherapy
Survival Rate
Survival
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Current management of epithelial carcinoma of the ovary. / Zucker, Peter; Rosenshein, N. B.

In: Comprehensive Therapy, Vol. 11, No. 5, 01.12.1985, p. 52-59.

Research output: Contribution to journalArticle

Zucker, Peter ; Rosenshein, N. B. / Current management of epithelial carcinoma of the ovary. In: Comprehensive Therapy. 1985 ; Vol. 11, No. 5. pp. 52-59.
@article{3826541a2a73421b8d0a408fddb3d1c2,
title = "Current management of epithelial carcinoma of the ovary",
abstract = "Most patients with epithelial cell cancer of the ovary are found to have advanced disease at the time of diagnosis (stage III or IV). Cytoreductive surgery should be attempted in all patients deemed appropriate surgical candidates. The goal of surgery is to remove as much tumor as feasible so that there are no isolated tumor implants within the abdominal cavity larger than 2 cm in diameter. Patients whose tumors can be resected to this extent are designated as having minimal residual disease (Group I). Patients in whom such cytoreductive surgery is not feasible or who are not appropriate surgical candidates usually have macroscopic residual disease (Group II). Group I patients, those with minimal residual disease, can be treated either with irradiation of the entire abdominal cavity or with systemic chemotherapy. The trend in most centers is to treat such patients with combination chemotherapy, although it remains unproven whether this is superior to radiation therapy. Group II patients, those with macroscopic residual disease, should not receive primary radiotherapeutic treatment. They may be treated with either single-agent or multiagent chemotherapy. While combination chemotherapy increases the chances of achieving a complete clinical response for individual patients, it is associated with increased toxicity. The risks associated with this toxicity must be considered in view of the fact that few of these patients will actually achieve such a response. The five-year survival rate for patients with epithelial cell cancer of the ovary has not changed for more than 30 years. Aggressive surgical, chemotherapeutic, and radiotherapeutic management is beginning to prolong survival. Hopefully, further investigation will allow the earlier diagnosis of patients with ovarian cancer and give the clinician new therapies for the management of this disease.",
author = "Peter Zucker and Rosenshein, {N. B.}",
year = "1985",
month = "12",
day = "1",
language = "English (US)",
volume = "11",
pages = "52--59",
journal = "Comprehensive Therapy",
issn = "0098-8243",
publisher = "Humana Press",
number = "5",

}

TY - JOUR

T1 - Current management of epithelial carcinoma of the ovary

AU - Zucker, Peter

AU - Rosenshein, N. B.

PY - 1985/12/1

Y1 - 1985/12/1

N2 - Most patients with epithelial cell cancer of the ovary are found to have advanced disease at the time of diagnosis (stage III or IV). Cytoreductive surgery should be attempted in all patients deemed appropriate surgical candidates. The goal of surgery is to remove as much tumor as feasible so that there are no isolated tumor implants within the abdominal cavity larger than 2 cm in diameter. Patients whose tumors can be resected to this extent are designated as having minimal residual disease (Group I). Patients in whom such cytoreductive surgery is not feasible or who are not appropriate surgical candidates usually have macroscopic residual disease (Group II). Group I patients, those with minimal residual disease, can be treated either with irradiation of the entire abdominal cavity or with systemic chemotherapy. The trend in most centers is to treat such patients with combination chemotherapy, although it remains unproven whether this is superior to radiation therapy. Group II patients, those with macroscopic residual disease, should not receive primary radiotherapeutic treatment. They may be treated with either single-agent or multiagent chemotherapy. While combination chemotherapy increases the chances of achieving a complete clinical response for individual patients, it is associated with increased toxicity. The risks associated with this toxicity must be considered in view of the fact that few of these patients will actually achieve such a response. The five-year survival rate for patients with epithelial cell cancer of the ovary has not changed for more than 30 years. Aggressive surgical, chemotherapeutic, and radiotherapeutic management is beginning to prolong survival. Hopefully, further investigation will allow the earlier diagnosis of patients with ovarian cancer and give the clinician new therapies for the management of this disease.

AB - Most patients with epithelial cell cancer of the ovary are found to have advanced disease at the time of diagnosis (stage III or IV). Cytoreductive surgery should be attempted in all patients deemed appropriate surgical candidates. The goal of surgery is to remove as much tumor as feasible so that there are no isolated tumor implants within the abdominal cavity larger than 2 cm in diameter. Patients whose tumors can be resected to this extent are designated as having minimal residual disease (Group I). Patients in whom such cytoreductive surgery is not feasible or who are not appropriate surgical candidates usually have macroscopic residual disease (Group II). Group I patients, those with minimal residual disease, can be treated either with irradiation of the entire abdominal cavity or with systemic chemotherapy. The trend in most centers is to treat such patients with combination chemotherapy, although it remains unproven whether this is superior to radiation therapy. Group II patients, those with macroscopic residual disease, should not receive primary radiotherapeutic treatment. They may be treated with either single-agent or multiagent chemotherapy. While combination chemotherapy increases the chances of achieving a complete clinical response for individual patients, it is associated with increased toxicity. The risks associated with this toxicity must be considered in view of the fact that few of these patients will actually achieve such a response. The five-year survival rate for patients with epithelial cell cancer of the ovary has not changed for more than 30 years. Aggressive surgical, chemotherapeutic, and radiotherapeutic management is beginning to prolong survival. Hopefully, further investigation will allow the earlier diagnosis of patients with ovarian cancer and give the clinician new therapies for the management of this disease.

UR - http://www.scopus.com/inward/record.url?scp=0022254490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022254490&partnerID=8YFLogxK

M3 - Article

C2 - 4006423

AN - SCOPUS:0022254490

VL - 11

SP - 52

EP - 59

JO - Comprehensive Therapy

JF - Comprehensive Therapy

SN - 0098-8243

IS - 5

ER -